

Ocrelizumab Biosimilar - Research Grade

Product Code: ICH5314

More Information

Species Reactivity: Human

Target: CD20

Concentration: 5mg/ml

Isotype: Human IgG1-kappa

Host: CHO Cells

product name H2: Ocrelizumab Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: P11836

Shipping Conditions: Blue ice

background: CD20 is a B-cell surface marker central to B-cell activation and proliferation and a long-established target in multiple sclerosis and B-cell malignancy research. This anti-human CD20 recombinant monoclonal antibody is supplied as an unconjugated, non-therapeutic analog of ocrelizumab for research use only. Produced to rigorous in vivo standards with low endotoxin, it is manufactured in scalable milligram (mg) to gram (g) quantities to serve bulk and high-throughput laboratories. The reagent is appropriate for B-cell depletion assays, in vitro functional screening, ADCC and CDC studies, and in vivo immunology and oncology models with dependable consistency.

Other names: MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7, membrane spanning 4-domains A1, FMC7

Specificity: Detects human CD20



Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.